FDA 503A Peptide Status Tracker

On July 23–24, 2026, FDA's Pharmacy Compounding Advisory Committee considered seven peptides for inclusion on the 503A bulk drug substances list and recommended six of them. This was not an FDA approval of any drug, and none of these substances is on the list today. The committee's role is advisory; FDA has not issued a final determination, and any change would come through notice-and-comment rulemaking.

This page tracks what was actually decided, what it means, and what has not happened yet. We maintain it because the distinction between "recommended for a compounding list" and "FDA approved" is being widely collapsed, and it is not a small difference.

For the broader argument behind this page — why this fight is happening at all — read our peptide access position paper.

The vote

Two things about this table are worth sitting with.

The margins were narrow. Six committee members voted against BPC-157 and one abstained. MOTS-c cleared 7–5–2. These were not consensus decisions, and a recommendation carried by two votes is not the same as a settled scientific question.

One substance was rejected. Emideltide — better known as DSIP, delta sleep-inducing peptide — was considered on the same record, by the same committee, on the same two days, and did not get a recommendation. We name it because a tracker that only lists the wins is a marketing page.

What a recommendation does, and what it does not

What it does

It is the advisory committee telling FDA that, on the evidence presented, these substances do not raise the safety concerns that would bar them from use in compounded preparations, and that there is a plausible basis for their use in compounding.

FDA usually follows PCAC. Not always — the agency has gone against the committee before.

What it does not do

It does not put anything on the 503A list. FDA is still reviewing docket comments and data. A change requires notice-and-comment rulemaking. Until that concludes, the regulatory status of these six substances is unchanged from what it was on July 22.

It is not FDA drug approval, and this route never produces one. These are different regulatory pathways that people routinely confuse:

A substance can sit on the 503A list forever and never be an FDA-approved drug. Inclusion means a compounding pharmacy may lawfully work with it. It is not a finding that it works.

It does not create evidence. The committee's recommendation does not change what the studies show. The published human evidence for these six substances remains thin — for several of them, essentially absent. A favorable vote on compounding eligibility is not a scientific endorsement, and anyone presenting it as one is misreading it.

What happens next

1. 1.FDA reviews the docket. Comments and data submitted through the public docket are still under review.
2. 2.FDA issues a proposed rule if it intends to add substances to the list. This is where the agency states its own position, which may differ from the committee's.
3. 3.Public comment period on the proposed rule.
4. 4.Final rule. Only at this point does a substance actually join the 503A list.

There is no published timeline. Any specific date you see quoted is speculation.

What this means if you are considering one of these

Nothing has changed yet. If a clinic or vendor is citing the July vote as a reason these are now available, that is incorrect.

"Research use only" is not a permission. RUO labeling is an exemption from the manufacturing standards that apply to drugs — not authorization for human use. Material sold that way has not been tested to any enforceable standard for identity, potency, sterility, or endotoxin content. For an injectable, those are not academic concerns, and independent testing of research-chemical peptides has repeatedly found contents that do not match the label.

BPC-157 remains on the WADA prohibited list regardless of its compounding status. Tested athletes should treat it as disqualifying.

A recommendation is not evidence of benefit. If you are weighing one of these, the question worth asking is what the human data actually show — which for most of this list is very little.

Substances not affected by this vote

Frequently confused with the six above. Their status is unchanged:

• Ipamorelin, CJC-1295, kisspeptin-10 — not among the seven considered; remain in the restrictive category of FDA's 503A review
• Semaglutide, tirzepatide — FDA-approved drugs; an entirely separate pathway
• Tesamorelin — FDA-approved as Egrifta since 2010 for HIV-associated lipodystrophy
• Sermorelin — approved as Geref in 1997, discontinued in 2008
• Investigational triple receptor agonists — in phase 3 trials; not approved, not lawfully available outside a trial

This page is educational and is not medical advice. Elevate Chicago is a telehealth practice serving patients nationwide. We do not compound, dispense, or sell any substance discussed here.